



Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer

SKOKIE, Ill., October 9, 2008 - Horizon Therapeutics, Inc., a privately held biopharmaceutical company, announced today that Robert J. De Vaere has joined the Company as executive vice president and chief financial officer.

"Bob is an experienced executive who brings more than 28 years of financial management experience to Horizon, including the last decade in healthcare with both public and private companies," said Timothy P. Walbert, president and chief executive officer. "During his career, Bob has been instrumental in numerous M&A transactions as well as an IPO and will be an important part of Horizon's future growth."

Mr. De Vaere's most recent position was as senior vice president, finance and administration and chief financial officer of IDM Pharma, Inc. (Nasdaq: IDMI), a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. Additionally, Mr. De Vaere served as vice president, finance and administration and chief financial officer of IDM Pharma from August 2005 to March 2006, and was vice president and chief financial officer of Epimmune from May 2000 until the business combination with IDM Pharma in August 2005.

Mr. De Vaere has also served as chief financial officer of Nexa Orthopedics, which was acquired by Tornier, Inc. and vice president of finance and administration and chief financial officer of Vista Medical Technologies, Inc., a medical device company.

Earlier in his career, Mr. De Vaere held accounting, finance and administrative positions within the electronics and aerospace industries. Mr. De Vaere received a bachelor's degree from the University of California, Los Angeles.

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy and patient compliance. For more information about the company and its products, please visit www.horizontherapeutics.com.

Contact:

Geoff Curtis
WeissComm Partners, Inc.
312-284-4701
gcurtis@wcpglobal.com